BridgeBio Pharma, Inc. (BBIO) — Total Liabilities
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $3.01B | +26.7% |
| 2024 | $2.38B | +25.8% |
| 2023 | $1.89B | +1.1% |
| 2022 | $1.87B | -0.6% |
| 2021 | $1.88B | +215.3% |
| 2020 | $595.70M | +282.6% |
| 2019 | $155.70M | +77.8% |
| 2018 | $87.58M | — |
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $3.01B | +26.7% |
| 2024 | $2.38B | +25.8% |
| 2023 | $1.89B | +1.1% |
| 2022 | $1.87B | -0.6% |
| 2021 | $1.88B | +215.3% |
| 2020 | $595.70M | +282.6% |
| 2019 | $155.70M | +77.8% |
| 2018 | $87.58M | — |